RT Journal Article
SR Electronic
T1 The COSEVAST Study: Unravelling the role of Arterial Stiffness in COVID-19 Disease severity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.18.20248317
DO 10.1101/2020.12.18.20248317
A1 Kumar, Sanjeev
A1 Kumar, Neeraj
A1 Kumar, Abhyuday
A1 Bhushan, Divendu
A1 Kumar, Amarjeet
A1 Kumar, Ajeet
A1 Singh, Veena
A1 Singh, Prabhat Kumar
YR 2020
UL http://medrxiv.org/content/early/2020/12/19/2020.12.18.20248317.abstract
AB Background Based on the detailed review of available research and case studies reported in reputed international journals, it can be concluded that endothelial damage (En-dotheliitis) both in small and large arteries may be an important factor of morbidity and mortality in COVID-19 patients. Arterial stiffness due to Endothelial Dysfunction has been established as an independent and specific marker of various chronic cardiovascular diseases.Objective Our objective was to examine functional impairment of the arteries in COVID-19 disease and establish the non-invasive measurement of Arterial Stiffness as an independent marker of disease severity.Methods We recorded the Arterial Stiffness of 23 Mild, 21 Moderate and 20 Severe COVID-19 patients grouped on latest NIH severity criteria. We observed Arterial Stiffness of COVID-19 patients with standard parameters like non-invasive Carotid-Femoral Pulse Wave velocity (cfPWV), Age-Normalized increase in cfPWV (ANI_cfPWV).Results Moderate and Severe COVID-19 patients have extremely elevated arterial stiffness than Mild patients. In Mild patients, cfPWV (829.1 ± 139.2 cm/s) was extremely significantly lower than both Moderate (1067 ± 152.5 cm/s, P< 0.0001) and Severe (1416 ± 253.9 cm/s, P < 0.0001) patients. ANI_cfPWV in Moderate and Severe patients was significantly higher than Mild patients. (Mild: 101.2 ± 126.1 cm/s; Moderate: 279 ± 114.4 cm/s; Severe: 580.1 ± 216.4 cm/s; intergroup P <0.0001). Conclusion: Our findings strongly suggest that arterial stiffness can be an independent and accurate marker for objective risk stratification and therapeutic alleviation of the acute cardiovascular complications like MODS in COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCTRI No.2020/10/028489Funding StatementNon FundedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This manuscript fulfilled all relevant ethical guidelines, and IRB and/or ethics committee approvals have been obtained. We obtained written approval of our Institutional Ethics Committee (IEC No. AIIMS/Pat/IEC/2020/595). This study design was registered with the Clinical Trials Registry of India (CTRI/2020/10/028489). Full name : Institutional Ethical committee, All India Institute of Medical Sciences Patna,Bihar,India. Decision : Ethical approval was given from IEC.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNA